KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

C Liu, S Zheng, Z Wang, S Wang, X Wang… - Cancer …, 2022 - Wiley Online Library
Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …
被引用次数：54 相关文章

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.

C Liu, S Zheng, Z Wang, S Wang, X Wang… - Cancer …, 2022 - europepmc.org
Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD-1) and its ligand PD-L1 have demonstrated potency towards treating patients …

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

C Liu, S Zheng, Z Wang, S Wang… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD-1) and its ligand PD-L1 have demonstrated potency towards treating patients …

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

C Liu, S Zheng, Z Wang, S Wang… - Cancer …, 2022 - search.proquest.com
Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …
[HTML] nih.gov

[HTML][HTML] KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

C Liu, S Zheng, Z Wang, S Wang, X Wang… - Cancer …, 2022 - ncbi.nlm.nih.gov
Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …